HIGHLIGHTS
- who: Giandomenico Roviello from the Department of Health Sciences, University of Florence, Florence, Italy, School of Human Health Sciences, University of have published the paper: Neoadjuvant Treatment in Muscle-Invasive Bladder Cancer: From the Beginning to the Latest Developments, in the Journal: (JOURNAL)
- what: Despite guideline recommendations, NAC prior to cystectomy is still seldom adopted.
SUMMARY
To date, cisplatin-based neoadjuvant chemotherapy (NAC) is the standard of care for MIBC and is associated with a 5% absolute survival benefit at 5 years and a 14% relative risk July 2022 | Volume 12 . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.